Charles River Labs Leverages New Leadership and Cost‑Savings Drive Margin Upside Amid Modest Revenue Dip

Birgit Girshick, who took the helm as chief executive this week, opened the call by framing the quarter as a transition point. “I step into this role with a clear understanding of Charles River today, what we can become and the tremendous responsibility we have to our clients, to the patients who rely on us, to our nearly 20,000 employees worldwide and also to you, our shareholders,” she said.

The tone was forward‑looking, emphasizing a refreshed strategic framework—dubbed “Pathway to Purpose”—that focuses on modernizing the business, sharpening the scientific portfolio and deepening client‑centricity.

The numbers reflected a mixed picture. Reported revenue of **$996 million** was up 1.2% year‑over‑year, but on an organic basis the company saw a 1.5% decline, in line with the low‑single‑digit drop the team had forecast in February. Non‑GAAP operating margin slipped 280 basis points to **16.3%**, and earnings per share fell 12% to **$2.06**.

The decline was driven primarily by higher stock‑compensation expense linked to the CEO transition, elevated non‑human‑primate (NHP) sourcing costs in the DSA (Drug Safety Assessment) segment and timing‑related revenue headwinds in the RMS (Research Models & Services) business.

Segment performance underscored the divergent trends. DSA revenue of **$597 million** fell 1.4% organically, with discovery‑service bookings lagging while safety‑assessment revenue held steady. The segment’s operating margin fell 290 bps to **21.0%**, reflecting higher direct study costs.

RMS revenue dropped 5.5% organically to **$208 million**, hit by a low‑point in NHP shipments and weaker small‑model sales in North America, though China‑based CRO demand partially offset the weakness. RMS margin fell 240 bps to **24.7%**. By contrast, the Manufacturing segment posted a **2.9%** organic revenue gain to **$191 million**, buoyed by strong microbial‑solutions demand, and its margin improved 280 bps to **25.9%** after leveraging higher volumes and cost‑saving initiatives.

Management highlighted that the quarter’s margin compression is largely “discrete” and expected to reverse. “We expect the second quarter operating margin to improve meaningfully from these levels as many of these first‑quarter discrete margin headwinds subside,” said CFO Glenn Coleman.

He pointed to the $100 million incremental cost‑savings target for 2026—part of a cumulative $300 million efficiency drive—as a key lever for margin expansion. The company also expects “over half” of the projected 500‑basis‑point improvement in the second half to stem from the recent acquisitions of K.F. Cambodia (now Charles River Cambodia) and PathoQuest, as well as the divestiture of the CDMO and Cell Solutions businesses completed in May.

The strategic reshaping is evident in the transaction activity. The acquisition of K.F. Cambodia and a controlling stake in Noveprim secure internal NHP supply for safety‑assessment studies, reducing reliance on third‑party farms.

The PathoQuest purchase adds an in‑vitro next‑generation sequencing platform for biologics quality control, expanding the firm’s NAM (New Approach Methodologies) capabilities. Meanwhile, the divestiture of the CDMO and Cell Solutions units, along with the planned sale of certain European discovery sites, trims non‑core assets and should lift operating margins by roughly 30 bps, according to management.

Analysts pressed for clarity on demand dynamics, especially the seasonality of DSA bookings and the health of the biotech pipeline. Birgit Girshick explained that “proposals and bookings start a little slow in the beginning of the year… then accelerate as budgets are approved and programs reprioritized.” She noted a “high‑single‑digit” year‑over‑year rise in proposal volume across both global biopharma and biotech segments, suggesting a pipeline of future bookings. However, she cautioned that early‑stage biotech demand remains “a little sluggish” despite a recent uptick in funding for mid‑size and late‑stage firms.

The conversation around AI and NAMs revealed both optimism and realism. While the firm sees AI‑driven drug discovery as a “long‑term tailwind,” Girshick admitted that “the sample set of AI‑discovered… drug programs is very, very small.” Nonetheless, the company is integrating AI into sales effectiveness, lead generation and lab automation, and it continues to expand its virtual control‑group (VCG) program, which aims to replace animal control groups without compromising scientific integrity.

Cash flow remained a concern. Free cash flow turned negative **$15 million** in the quarter, largely due to performance‑based bonuses for 2025. CapEx slipped modestly to **$56 million**. The firm repurchased **$200 million** of its own stock under a $1 billion authorization, signaling confidence in its long‑term strategy despite the short‑term cash burn.

Guidance for the full year was reaffirmed, albeit with a modest adjustment for foreign‑exchange headwinds. The company continues to expect organic revenue to decline **0.5%–1.5%**, with non‑GAAP EPS projected at **$10.80–$11.30** (5%–10% growth YoY). Reported revenue is now forecast to fall **4.0%–5.5%**, reflecting a weaker dollar. The firm anticipates operating‑margin improvement of **120–150 bps** for 2026, with the bulk of the uplift occurring in the second half as cost‑savings materialize and the impact of divestitures is fully realized.

The market’s reaction was muted. Charles River’s shares traded at **$181.68**, down a mere **0.03%** on the day, though the stock has risen **8.81%** over the past week, still lagging **8.92%** YTD and sitting about **20.6%** below its 52‑week high. The modest price movement suggests investors are digesting the nuanced outlook: a near‑term revenue dip offset by a clear path to margin expansion and a strategic refocus under new leadership.

Overall, Charles River’s first‑quarter story is less about headline growth and more about positioning. By tightening its cost base, securing critical supply chains and shedding non‑core assets, the firm is betting that a leaner, more technology‑enabled operation will capture a larger share of a biopharma market that is gradually emerging from a period of budget tightening and funding uncertainty.